Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Lessened by Wrapmanager Inc.

Wrapmanager Inc. reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 10.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,048 shares of the pharmaceutical company’s stock after selling 245 shares during the period. Wrapmanager Inc.’s holdings in Vertex Pharmaceuticals were worth $825,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Highline Wealth Partners LLC bought a new position in Vertex Pharmaceuticals during the third quarter valued at approximately $27,000. Dunhill Financial LLC increased its stake in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $30,000. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the third quarter worth $35,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the sale, the executive vice president now directly owns 64,021 shares in the company, valued at $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Trading Down 0.5 %

Shares of VRTX stock opened at $481.65 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The firm has a fifty day moving average of $436.32 and a 200-day moving average of $460.68. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The stock has a market cap of $123.68 billion, a price-to-earnings ratio of -218.93, a P/E/G ratio of 2.11 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $550.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and raised their price objective for the company from $500.00 to $550.00 in a research note on Monday, December 9th. Bank of America decreased their target price on Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating for the company in a research report on Thursday, December 19th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and lifted their price target for the company from $408.00 to $424.00 in a research report on Tuesday, February 11th. Finally, Citigroup began coverage on shares of Vertex Pharmaceuticals in a report on Thursday, November 14th. They set a “buy” rating and a $575.00 price objective for the company. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $506.70.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.